Cargando…
Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
BACKGROUND: Improving outcomes of patients with glioblastoma (GBM) represents a significant challenge in neuro-oncology. We undertook a systematic review of key parameters of phase II and III trials in GBM to identify and quantify the impact of trial design on this phenomenon. METHODS: Studies betwe...
Autores principales: | Balasubramanian, Adithya, Gunjur, Ashray, Hafeez, Umbreen, Menon, Siddharth, Cher, Lawrence M, Parakh, Sagun, Gan, Hui Kong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850118/ https://www.ncbi.nlm.nih.gov/pubmed/33543145 http://dx.doi.org/10.1093/noajnl/vdaa171 |
Ejemplares similares
Ejemplares similares
-
Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020) -
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021) -
Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022) -
Biomarkers and smart intracranial devices for the diagnosis, treatment, and monitoring of high-grade gliomas: a review of the literature and future prospects
por: Hafeez, Umbreen, et al.
Publicado: (2019) -
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
por: Gunjur, Ashray, et al.
Publicado: (2019)